US 12,077,788 B2
Production of a mixture of neutral non-fucosylated oligosaccharides by a cell
Sofie Aesaert, Zwijnaarde (BE); Joeri Beauprez, Zwijnaarde (BE); Pieter Coussement, Zwijnaarde (BE); Thomas Decoene, Zwijnaarde (BE); Nausicaä Lannoo, Zwijnaarde (BE); Gert Peters, Zwijnaarde (BE); Kristof Vandewalle, Zwijnaarde (BE); and Annelies Vercauteren, Zwijnaarde (BE)
Assigned to INBIOSE N.V., Zwijnaarde (BE)
Appl. No. 18/040,629
Filed by INBIOSE N.V., Zwijnaarde (BE)
PCT Filed Aug. 10, 2021, PCT No. PCT/EP2021/072265
§ 371(c)(1), (2) Date Feb. 3, 2023,
PCT Pub. No. WO2022/034071, PCT Pub. Date Feb. 17, 2022.
Claims priority of application No. 20190198 (EP), filed on Aug. 10, 2020; application No. 20190200 (EP), filed on Aug. 10, 2020; application No. 20190201 (EP), filed on Aug. 10, 2020; application No. 20190202 (EP), filed on Aug. 10, 2020; application No. 20190203 (EP), filed on Aug. 10, 2020; application No. 20190204 (EP), filed on Aug. 10, 2020; application No. 20190205 (EP), filed on Aug. 10, 2020; application No. 20190206 (EP), filed on Aug. 10, 2020; application No. 20190207 (EP), filed on Aug. 10, 2020; application No. 20190208 (EP), filed on Aug. 10, 2020; application No. 21168997 (EP), filed on Apr. 16, 2021; application No. 21186202 (EP), filed on Jul. 16, 2021; and application No. 21186203 (EP), filed on Jul. 16, 2021.
Prior Publication US 2023/0265399 A1, Aug. 24, 2023
Int. Cl. C12N 9/10 (2006.01); C12N 1/00 (2006.01); C12N 1/20 (2006.01); C12N 5/00 (2006.01); C12N 15/52 (2006.01); C12N 15/70 (2006.01); C12P 7/58 (2006.01); C12P 19/12 (2006.01); C12P 19/18 (2006.01); C12P 19/26 (2006.01)
CPC C12N 9/1048 (2013.01) [C12N 1/00 (2013.01); C12N 1/20 (2013.01); C12N 5/00 (2013.01); C12N 9/1029 (2013.01); C12N 9/1051 (2013.01); C12N 9/1096 (2013.01); C12N 15/52 (2013.01); C12N 15/70 (2013.01); C12P 7/58 (2013.01); C12P 19/12 (2013.01); C12P 19/18 (2013.01); C12P 19/26 (2013.01); C12Y 203/01004 (2013.01); C12Y 204/00 (2013.01); C12Y 206/01016 (2013.01); C12N 2500/34 (2013.01)] 27 Claims
 
1. A metabolically engineered cell that produces a mixture of at least four different neutral non-fucosylated mammalian milk oligosaccharides, wherein said cell:
is metabolically engineered for production of said mixture,
expresses at least two different glycosyltransferases involved in producing the mixture of at least four different neutral non-fucosylated mammalian milk oligosaccharides, wherein each of said at least two glycosyltransferases is selected from the group consisting of a galactosyltransferase, an N-acetylglucosaminyltransferase, and an N-acetylgalactosaminyltransferase, and
is capable of synthesizing at least one nucleotide-sugar, wherein each nucleotide-sugar is a donor for at least one glycosyltransferase.